Overview

Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

Status:
Terminated
Trial end date:
2020-09-24
Target enrollment:
Participant gender:
Summary
This phase II trial investigates whether patients greater than or equal to 65 years of age diagnosed with myeloma or another plasma cell malignancy will have better outcomes with transplant followed by maintenance therapy, as primarily measured by progression-free survival, versus non-transplant approaches.
Phase:
Phase 2
Details
Lead Sponsor:
Margarida Magalhaes-Silverman
University of Iowa
Collaborator:
National Cancer Institute (NCI)
Treatments:
BB 1101
Bortezomib
Cisplatin
Cyclophosphamide
Dexamethasone
Dexamethasone 21-phosphate
Dexamethasone acetate
Doxorubicin
Etoposide
Etoposide phosphate
Liposomal doxorubicin
Melphalan
Thalidomide